AstraZeneca, Britain’s largest pharmaceutical company, has announced a £300 million investment in the United Kingdom, marking a significant reversal after it had previously stalled large-scale projects in the country. The drugmaker had scaled back its investments due to concerns over the business environment, including the availability of new medicines on the NHS and drug pricing policies.
Investment Details
The company will allocate £200 million to complete the construction of an office building on its Cambridge campus, known as the Disc, which will be named the Rosalind Franklin centre. Additionally, £100 million will be directed towards developing a ‘lab of the future’ at its Macclesfield site, utilising digital and data tools to accelerate drug development. This announcement was made by Prime Minister Keir Starmer in the House of Commons, who emphasised that the investment would safeguard jobs.
Pascal Soriot, AstraZeneca’s chief executive, confirmed that the Cambridge project, which had been paused last September, will now be completed. The new office will house scientists involved in data analysis and molecular research, relocating staff from other buildings. In Macclesfield, the investment is expected to create new scientific positions, though the exact number has not been specified.
Context and Previous Pauses
Last year, AstraZeneca paused a £200 million expansion in Cambridge and earlier scrapped plans for a £450 million vaccine manufacturing facility in Speke, Merseyside, citing reduced government support after lengthy negotiations. The company employs approximately 10,000 people in the UK, with over 4,000 in Cambridge, a similar number in Macclesfield, 2,000 across London and Luton, and 400 in Speke.
Starmer noted that the investment was made possible by a pharmaceutical pricing agreement between the UK and the United States, finalised in December. This deal is expected to lower prescription drug prices in the US while increasing NHS spending on medicines, and it protects UK pharmaceutical companies from trade tariffs. Soriot expressed gratitude to the UK government for improving patient access to medicines, citing four new drug approvals since the start of the year.
Industry Reaction
Science Secretary Liz Kendall hailed the investment as a significant vote of confidence in the UK’s science community. Susannah Streeter, chief investment strategist at Wealth Club, described the move as “super encouraging” and a sign of renewed momentum for the pharmaceutical industry in the UK. She highlighted the symbolic importance of restarting the Cambridge expansion, demonstrating the government’s efforts to attract big pharma.
However, the £300 million investment is relatively modest compared to AstraZeneca’s $50 billion commitment to US research and manufacturing announced last October, and its $15 billion drive in China.
Financial Performance
Earlier on Wednesday, AstraZeneca reported an 8% increase in revenues to $15.3 billion for the first quarter, driven by 16% growth in oncology and a 15% rise in rare disease treatments. Cancer drugs now account for nearly half of total sales. The company aims to achieve 25 blockbuster drugs—each generating over $1 billion annually—by 2030, with a target of $80 billion in sales.
Meanwhile, GSK also reported strong sales, with a 5% rise to £7.6 billion, including 28% growth in cancer drug sales. However, GSK’s vaccine revenues faced headwinds in the US, partly due to scepticism from the Trump administration. The company expects total turnover growth of 3% to 5% this year and maintains its target of £40 billion in sales by 2031.
Broader Life Sciences Boost
The Association of the British Pharmaceutical Industry noted a “remarkable month for UK life sciences,” with companies investing £1.4 billion since the Anglo-US drug pricing deal. This includes £500 million from Belgium’s UCB Pharma and $500 million from Bristol Myers Squibb. Last week, German firm Boehringer Ingelheim announced a £150 million AI centre in London’s King’s Cross, set to house 50 AI experts by 2027.
